What These Labels Report About Patients 65 and Over

Answer first: the same conclusion, printed over very different numbers

All six of the approved prescribing documents read here carry a subsection numbered 8.5 and titled Geriatric Use. Federal regulation requires it, and defines it as covering persons 65 years of age and older unless the label says otherwise.

Every one of the six states that no overall difference in safety or effectiveness was observed between older and younger adult patients in at least one trial set. Read only that line and the six documents look identical.

The figures underneath the line are not identical. The share of treated patients aged 65 and over runs from roughly one in eight in one program to more than half in one trial. That depends far more on which indication was being studied than on which molecule was involved.

Two of the six also carry something the other four do not. One reports that a question could not be answered for one of its indications. One reports observed differences in its oldest patients, with a limiting clause attached that changes what the observation means.

The regulation writes three sentences and lets the evidence pick one

Before reading any label it helps to know what the format allows, because the choice between the options is itself a piece of information.

The regulation sets out three alternatives. The first is for studies that did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. The second is for studies that did include enough for a difference to have shown up, where none did. The third is for evidence that use in older patients is associated with differences in safety or effectiveness, or requires specific monitoring or a dosage adjustment.

The second option comes with a fixed tail. It closes by saying that greater sensitivity of some older individuals cannot be ruled out. It also asks the label to print what proportion of subjects in the clinical studies were 65 and over, and what proportion were 75 and over.

All three prescribed forms close with an instruction addressed to the prescriber rather than to the reader, so they are described here rather than quoted. The third option asks for a brief description of any observed difference, with cross-references to the sections that hold the detail.

Across these six documents, all three options are in use. Four labels use the second form alone, one adds the first form for a second indication, and one reports observed differences.

The weight trials enrolled the fewest older patients by a wide margin

This is the clearest pattern in the six, and it lines up with indication rather than with molecule.

In the two pooled weight-reduction studies on the tirzepatide weight label, 226 treated patients were 65 or older, which the label puts at 9 percent. Thirteen were 75 or older, which it puts at 0.5 percent. On the semaglutide weight label, the injection trials for weight reduction counted 233 patients aged 65 to under 75, at 9 percent, and 23 aged 75 and older, at 1 percent. The orforglipron label reports 399 treated patients aged 65 or older across its first two trials, at 13 percent, and 33 aged 75 or older, at 1 percent.

Now the same molecules under other indications. The semaglutide diabetes label reports 744 treated patients aged 65 and over in its pooled glycemic control trials, at 23.6 percent, and 788 in its cardiovascular outcome trial, at 48 percent. The tirzepatide diabetes label reports 1,539 across a pool of seven trials, at 30.1 percent, and 3,327 in a cardiovascular outcomes trial, at 50 percent. The oral semaglutide document reports 30 percent across its glycemic control pool and 56 percent in one cardiovascular outcomes trial.

The gap is large and consistent. The trials behind the weight indications enrolled older adults at roughly a tenth of the population, while the cardiovascular and diabetes trials for the same molecules ran between a quarter and more than half.

None of that is hidden, and none of it is a criticism of any trial. It reflects who has the conditions being studied. It does mean that a figure taken from one of these labels describes a different mix of ages depending on which trial produced it.

One label says the question could not be answered, for one indication only

The tirzepatide weight label is the only one of the six that uses the regulation's first prescribed form, and it uses it alongside the second in the same subsection.

For its two pooled weight-reduction studies it uses the second form. It reports the counts above, and states that no overall differences in safety or effectiveness were observed between patients 65 and older and younger adult patients.

For its two obstructive sleep apnea studies it switches. Those studies, it states, did not include sufficient numbers of patients aged 65 or older to determine whether they respond differently from younger adult patients. It then adds that other reported clinical experience with the molecule has not identified differences in responses between older and younger patients.

One document, one subsection, two different answers, because two different trial programs supported two different indications. It is a useful illustration that a geriatric statement attaches to a body of evidence rather than to a drug.

One label reports differences in its oldest patients, and the sentence has a second half

The semaglutide weight label is the only one of the six to use the regulation's third form, and reading it to the end is the whole point of this section.

It first states that no overall difference in effectiveness was observed between patients aged 65 and older and younger adult patients. Then it reports two observations from its cardiovascular outcomes trial.

The first: patients aged 75 and older reported more hip and pelvis fractures in the treated arm than in the placebo arm. The second is the one that is easy to truncate. Patients aged 75 and older, in the treated arm and the placebo arm alike, reported more serious adverse reactions overall than younger adult patients did.

That parenthesis is doing real work. The first observation is a comparison between arms within one age band. The second is a comparison between age bands across both arms, which describes the population rather than the drug. Quoting the first half of the second sentence alone would turn one into the other.

The same label carries a third trial set with its own figures, in patients with a liver condition, where it reports no overall differences between older and younger adult patients.

The clause about greater sensitivity appears once in six documents

The regulation's second prescribed form ends with the words that greater sensitivity of some older individuals cannot be ruled out. It reads like standard label furniture, and across these six it is not.

Read across all six documents, that clause appears on one label only, the semaglutide diabetes label. The other five carry the no-overall-difference finding without it.

The regulation itself explains how that is possible. It offers the prescribed statements as wording a manufacturer must use or reasonably adapt. It then adds that where a sponsor believes none of them is appropriate, the sponsor must give reasons and may propose an alternative, which the agency may permit.

So the presence of the clause on one label and its absence from five is a fact about the documents. It is not, on its own, a difference between the molecules.

Two age brackets that look the same and are not

Anyone comparing these percentages across labels runs into a small trap that is easy to miss and hard to unsee.

Five of the six count patients as 65 years of age and older, a band that includes everyone above 75. The semaglutide weight label instead reports patients aged 65 to less than 75 as one figure and patients aged 75 and older as a second.

The consequence is arithmetic. Two labels that both print 9 percent are not printing the same quantity. On one it is everyone 65 and over. On the other it is everyone 65 to under 75, with the oldest band reported separately.

It is a reminder that a percentage on a label carries its own denominator and its own boundaries. Both belong in the sentence with the number whenever one of these figures is repeated.

What a figure in this subsection is, and what it is not

A percentage here counts the people who were enrolled in and treated during a set of clinical studies. It is a description of a trial population, in the same family as the baseline characteristics reported further back in the same document.

It is not an eligibility rule, and the regulation does not treat it as one. Rules about who a drug should not be used in sit in the contraindications section, under a standard requiring a known hazard rather than a theoretical possibility.

It is also not the trial's entry criteria. Those are reported in the clinical studies section and define who a particular result describes, which a companion article on this site works through in detail.

Where any of this bears on treatment, a prescriber and a pharmacist are the people who can answer it, and the subsection itself is short enough to read in a minute before that conversation.